Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.68
Nov 13 • 3:58 PM ET Dollar change-0.11 Percentage change(-6.15%)
Aftermarket Close
1.93
Aftermarket • 6:44 PM ET Dollar change+0.25 Percentage change(14.88%)
Index
-
Market Cap
2.84M
Enterprise Value
-2.43M
Income
-13.97M
Sales
0.00M
Book/sh
2.64
Cash/sh
3.30
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Aug 29, 1991
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.64
P/C
0.51
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.57
Current Ratio
2.57
Debt/Eq
0.07
LT Debt/Eq
0.03
Option/Short
No / Yes
EPS (ttm)
-17.04
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
73.56% 69.90%
Sales past 3/5Y
- -
EPS Y/Y TTM
85.64%
Sales Y/Y TTM
-100.00%
EPS Q/Q
49.97%
Sales Q/Q
-
Insider Own
30.04%
Insider Trans
0.00%
Inst Own
8.08%
Inst Trans
8.48%
ROA
-210.27%
ROE
-352.43%
ROIC
-310.94%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-15.13%
SMA50
-38.85%
SMA200
-71.74%
Trades
Shs Outstand
1.65M
Shs Float
1.18M
52W High
40.24 -95.83%
52W Low
1.73 -3.13%
Volatility
13.22% 9.82%
ATR (14)
0.23
RSI (14)
31.22
Beta
2.74
Rel Volume
0.62
Avg Volume
45.80K
Volume
28,264
Perf Week
-10.64%
Perf Month
-22.58%
Perf Quarter
-58.62%
Perf Half Y
-87.67%
Perf YTD
-94.40%
Perf Year
-95.72%
Perf 3Y
-99.61%
Perf 5Y
-100.00%
Perf 10Y
-100.00%
Prev Close
1.79
Price
1.68
Change %
-6.15%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cherington Charles10% OwnerFeb 10 '26Buy0.504,000,0002,000,0006,779,440Feb 17 09:14 PM
Ernexa Therapeutics, Inc. engages in the research and development of cellular therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. Its pipeline includes ERNA-101 (Ovarian Cancer) and ERNA-201 (Rheumatoid Arthritis). The company was founded in 1984 and is headquartered in Cambridge, MA.
CEOMr. Sanjeev Luther
CITPMr. Mark J. Keeley CPA
Head of CMC & OperationsMs. Deborah Vee Wild
Chief Scientific OfficerDr. Robert Hamilton Pierce M.D.
General CounselMs. Dorothy J. Clarke